DJIA 16,441.58 16.73 0.10%
NASDAQ 4,106.52 20.30 0.50%
S&P 500 1,867.36 5.05 0.27%
market minute promo



company name or ticker

ImmunoGen's CEO Presents at 2013 Credit Suisse Healthcare Conference (Transcript)

ImmunoGen Rises on Licensing Deal - Analyst Blog

1 Big Pharma Stock's Big, Bold Moves

Novartis is selling off one of its major businesses. What does this mean for shareholders?

Why ImmunoGen Inc. Shares Roared Higher

ImmunoGen reminds shareholders that two heads are most often better than one!

UPDATE: Morgan Stanley Downgrades ImmunoGen Following Phase 2 Failure of IMGN901

Today's Perilous Reversal Stock: Immunogen (IMGN)

Sector Update: Healthcare Shares Mixed Pre-Market; Progenics Reports Better-Than-Expected Net Loss

Top Analyst Upgrades and Downgrades: Twitter, Best Buy, Exxon and More

Sector Update: Healthcare

Benzinga's Top #PreMarket Losers

See More Articles...